Pharmacogenomics and Effective Treatment With Clopidogrel

Avera McKennan Hospital & University Health Center

Status: Completed

Conditions: Pharmacogenomics and Cardiovascular Events

Treatments: Genetic: Pharmacogenomics

Study type: Observational

Funder types: Other

Identifiers

NCT01611545

AIHG-1410-Clopidogrel

Details and patient eligibility

About

The aim of this biospecimen repository is to evaluate an individual's genotype, identify the variances, and understand how they relate to treatment with clopidogrel.

Full description

The objective of this project is to distinguish genetic profiles that will assist a practitioner in determining the right dose or alternate medication for the patient. In partnership with the genetics team of the Avera Institute for Human Genetics and physicians with the Avera Heart Hospital of South Dakota and North Central Heart Institute, the research team will perform genetic analysis to identify genetic variances.

Enrollment: 130 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Currently taking or prescribed Clopidogrel or under consideration
• Acute/interventionPatients of the Avera Heart Hospital
• Cardiology clinic patients with the Avera Heart Hospital and North Central Heart Institute

Exclusion criteria

• Unable to provide informed consent

Trial design

130 participants in 1 patient group

Clopidogrel

Description:

Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment

Treatment:

Genetic: Pharmacogenomics